Stcube,

Global Innovation-Driven Biopharmaceutical Company STCube Pharmaceuticals develops therapies to overcome novel immune evasion mechanisms in cancer. As a subsidiary of STCube, an international firm with diverse holdings, we are focused on finding and exploiting new targets in the immune-oncology field and growing as a research-driven biopharmaceutical company. STCube Pharmaceuticals research center is located near the NIH and FDA in Gaithersburg, MD. Immune-checkpoint inhibitors, which block immune-suppressive signals from cancer and support the patient’s natural anticancer immune response, are at the center of global anti-cancer research. We strive to provide breakthrough cancer therapies through our inventive and innovative platform for new drug development and cutting-edge research. Our mission is to provide cancer patients with meaningful therapeutic efficacy and improvement in quality of life through innovative “First in Class” and “Best in Class” anti-cancer therapies. The company was formerly known as Schem Co., Ltd. and changed its name to STCube, Inc. In April 2008. STCube, Inc. was founded in 1989 and is headquartered in Seoul, South Korea.